Loxo '292 And Cancer Drug Development Today: So Much Promise, So Many Questions
Loxo data on the RET inhibitor LOXO-292 impressed at ASCO, so much so the company is looking to talk to regulators about the results after only a single-arm Phase I trial – but it's not a silver bullet as a tissue-agnostic treatment. Data on a separate target, PI3K, underwhelmed in breast cancer. Tissue of origin remains important, though the reasons why are not entirely understood.
You may also be interested in...
The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292. An NDA submission is on track for later this year.
Lilly hopes to bring Loxo’s tissue-agnostic RET inhibitor selpercatinib to market in 2020.
An EU filing by licensee Bayer puts Loxo Oncology’s larotrectinib on track to be the first tropomysosin receptor kinase inhibitor to reach the market there. Meanwhile, Loxo’s second product, LOXO-292, is speeding its way to a US filing.